Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2313 results

India’s Dept of Biotech plans financial help for the biotech industry

India’s Dept of Biotech plans financial help for the biotech industry

15-09-2014

Anti-cancer compounds, immunogens against H1N1, cheap recombinant human insulin, stem cell research -…

BiotechnologyFinancialIndiaResearch

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Merck Serono pulls plug on tecemotide in Stage III NSCLC

Merck Serono pulls plug on tecemotide in Stage III NSCLC

12-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, is to discontinue the clinical development…

BiotechnologyGermanyMerck SeronoOncologyResearch

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

12-09-2014

US biotech firm Biogen Idec has reported data confirming its Plegridy gives provides treatment effects…

Biogen IdecBiotechnologyNeurologicalPlegridyResearchUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

11-09-2014

Clinical stage oncology drug development company MabVax Therapeutics has entered agreements with Memorial…

BiotechnologyCancer therapeuticsChimeric antigen receptorMabVax TherapeuticsOncologyResearchUSA

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

ReproCELL acquires the iPS Cell Business unit of Stemgent

10-09-2014

Japan-based ReproCELL is to acquire the iPS Cell Business unit of Privately-held US firm Stemgent. This…

BiotechnologyMergers & AcquisitionsReproCELLStemgent

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

Value of patents as enabling and supporting medical research stressed by AusBiotech

09-09-2014

Patents are at the core of enabling genetic tests, treatments, vaccines and cures resulting from medical…

AustraliaBiotechnologyPatentsResearch

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

Hyperion terminates DaiPep277 program due to "misconduct"

08-09-2014

Shares of Hyperion Therapeutics’ plunged 11% to $24.61 in pre-market trading today, after the company…

Andromeda BiotechAndromeda GalaxyAstronomyBiotechnologyDiabetesDiaPep277HyperionHyperion TherapeuticsResearchUSA

Eisai divests US Zonegran rights to Concordia

Eisai divests US Zonegran rights to Concordia

07-09-2014

Japanese drugmaker Eisai (TYO: 4523) says its US subsidiary has entered into an agreement to divest its…

BiotechnologyConcordia PharmaceuticalsEisaiMergers & AcquisitionsNeurologicalUSAZonegran

1 to 25 of 2313 results

Back to top